Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gensight BiologicsGSGTF EV-to-EBITDA is -3.27 as of Jul. 26, 2026. The stock has 8 warning signs investors should review. Among 402 Biotechnology companies, Gensight Biologics ranks worse than 248755.97% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Gensight Biologics's enterprise value is $32.99 Mil.
Gensight Biologics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-10.08 Mil. Therefore, Gensight Biologics's EV-to-EBITDA for today is -3.27.
The historical rank and industry rank for Gensight Biologics's EV-to-EBITDA or its related term are showing as below:
GSGTF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.33 Med: -2.49 Max: -0.88
Current: -3.42
During the past 13 years, the highest EV-to-EBITDA of Gensight Biologics was -0.88. The lowest was -9.33. And the median was -2.49.
GSGTF's EV-to-EBITDA is ranked worse than 100% of 402
companies
in the Biotechnology industry
Industry Median: 12.2
vs GSGTF: -3.42
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gensight Biologics's PE Ratio (TTM) for today is calculated as:
Gensight Biologics's share price for today is $0.09.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gensight Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.093.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Gensight Biologics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GSGTF vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Gensight Biologics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gensight Biologics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gensight Biologics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gensight Biologics's EV-to-EBITDA falls into.
Gensight Biologics's current Enterprise Value is $32.99 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gensight Biologics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-10.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gensight Biologics (GSGTF) has a EV-to-EBITDA of -3.27 as of Jul. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gensight Biologics. According to the industry distribution chart, Gensight Biologics ranks #999999 out of 402 companies in the Biotechnology industry.
Is Gensight Biologics' EV-to-EBITDA too high?
Gensight Biologics' current EV-to-EBITDA is -3.27. Based on the distribution chart, Gensight Biologics ranks #999999 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Gensight Biologics' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gensight Biologics ranks #999999 out of 402 companies for EV-to-EBITDA. This places Gensight Biologics in the lower half of its industry. The industry median EV-to-EBITDA is 12.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.20, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gensight Biologics. For the Biotechnology industry, the median EV-to-EBITDA is 12.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gensight Biologics's current EV-to-EBITDA is -3.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Gensight Biologics (GSGTF) has a current EV-to-EBITDA of -3.27. The current EV-to-EBITDA is -3.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Gensight Biologics (GSGTF), the current EV-to-EBITDA is -3.27 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GSGTF has been successfully added to your 
